What is ALK-positive Non-Small Cell Lung Cancer X-396 Phase I/II Clinical Trial?

Category: Others

false

NCT01625234 is a randomized, interventional, single group assignment, to assess the maximum tolerated dose of an investigational medication (ensartinib).

No patients have reported taking ALK-positive Non-Small Cell Lung Cancer X-396 Phase I/II Clinical Trial.
Last updated:
There are no evaluations for ALK-positive Non-Small Cell Lung Cancer X-396 Phase I/II Clinical Trial.